BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20180101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190625
DTEND;VALUE=DATE:20190628
DTSTAMP:20260514T232713
CREATED:20190418T090640Z
LAST-MODIFIED:20190418T090640Z
UID:20372-1561420800-1561679999@www.pharmajournalist.com
SUMMARY:2nd Combination Products Lifecycle Management Summit
DESCRIPTION:Returning to Boston for its 2nd successful year in 2019\, the CPLM Summit features a fresh speaker line-up including the FDA\, Alnylam\, kaleo\, Novartis and many others\, as well as a pre-conference focus day to give you a comprehensive LCM guide to your combination products. \n \nLifecycle management for drug-device combination product has stolen the spotlight amongst pharma\, biotechs and device developers. Integrating multiple project teams and defining a common LCM program can be difficult – but there is a lot of potential and many benefits to having such a mind-set and implementing a robust LCM program from the get-go. \nAs the only peer-led community\, we will bring in 100+ senior leaders from drug-device teams including the regulatory affairs\, product development and quality to share their view and encourage collaborative efforts. \nFor more information on 2nd Annual CPLM Summit\, visit https://ter.li/11hr26
URL:https://www.pharmajournalist.com/event/2nd-annual-cplm-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190625
DTEND;VALUE=DATE:20190628
DTSTAMP:20260514T232713
CREATED:20190426T082151Z
LAST-MODIFIED:20190426T082638Z
UID:20510-1561420800-1561679999@www.pharmajournalist.com
SUMMARY:Cell Engager Summit
DESCRIPTION:The Cell Engager Summit is the only meeting focused on developing multi-specific cell engaging therapies in liquid and solid tumor indications; accelerating early discovery innovation into the clinic. \n \nOvercome safety and toxicity challenges by increasing target specificity and improved cellular trafficking through informed target selection to ensure enhanced efficacy of your cell engager drug. \nDiscover how to effectively scale complicated manufacturing of multispecific cell engagers to reduce production costs and time whilst ensuring purity and quality of antibodies. \nWith 22+ hours of content\, 2 interactive workshops and over 5 hours of networking with key industry leaders\, this conference will focus solely on cell engaging drugs and how to tackle key clinical and commercial challenges. \nJoin us as we unite experts from across large pharma\, innovative biotech and solution and service providers to bring to market safe and effective multi-specific immune cell engaging therapies. \nTo learn more and to register online\, visit cell-engager-summit.com
URL:https://www.pharmajournalist.com/event/cell-engager-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190626
DTEND;VALUE=DATE:20190629
DTSTAMP:20260514T232713
CREATED:20190225T142502Z
LAST-MODIFIED:20190225T142702Z
UID:19737-1561507200-1561766399@www.pharmajournalist.com
SUMMARY:4th Microbiome Movement – Drug Development Summit
DESCRIPTION:4th Microbiome Movement – Drug Development Summit\nJune 26-28\, 2019 | Boston\, MA \n \nReturning for the fourth year\, the Microbiome Movement – Drug Development Summit continues to be the industry-leading forum to help forward thinking researchers from the pharmaceutical\, biotech and academic community pursue the causal role of the human microbiome in disease\, to create a new generation of targeted treatments that demonstrate consistent clinical outcomes and predictable MoAs. \nIf you are\, or would like to be\, a player in the microbiome arena\, this is the conference you should attend to not only hear the latest pre-clinical and clinical development from organizations developing microbiome-based therapeutics\, biomarkers and diagnostics\, but also make long-lasting connections that will accelerate your microbiome developments forward\, and help translate this promising science into a reality for patients. \nHear from 60+ expert speakers including: \n\nAlison Lawton\, CEO\, Kaleido Biosciences\nBernat Olle\, CEO\, Vedanta Biosciences\nCathryn Nagler\, Bunning Food Allergy Professor\, University of Chicago\nEric Shaff\, CEO\, Seres Therapeutics\nEsi Lamouse-Smith\, Director\, Janssen Pharmaceuticals\nKen Blount\, CSO\, Rebiotix\nMike Romanos\, CEO\, Microbiotica\nUlrich Thienel\, Chief Medical Officer\, Finch Therapeutics Group\n\nSee the complete agenda and speaker list: https://ter.li/nefsqj \nEarly booking rates and group discounts are available. Visit the website to learn more: https://ter.li/1bcb5n.
URL:https://www.pharmajournalist.com/event/4th-microbiome-movement-drug-development-summit/
LOCATION:Revere Boston Common Hotel\, 200 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@microbiome-movement.com
END:VEVENT
END:VCALENDAR